logo-loader
viewSeelos Therapeutics

Seelos Therapeutics wins key meeting with European regulator to propose Trehalose study for Sanfilippo syndrome

It has set up a meeting with the European Medicines Agency in March 2020 for scientific advice and assistance over a clinical study in Europe

Seelos Therapeutics -
The EMA offers guidance for the research and advance of treatments for rare diseases across the EU

Seelos Therapeutics Inc (NASDAQ:SEEL), the biotech company, has won a crucial advance in its development plans in Europe and the US for trehalose (SLS-OO5), its investigational molecule, which takes aim at a number of neurodegenerative diseases. 

The New York company has succeeded in setting up a meeting in March this year with the European Medicines Agency to seek scientific advice and assistance for a clinical study in Europe of trehalose, to assess its effectiveness in treating patients with Type A and B versions of Sanfilippo syndrome, a rare childhood disorder that triggers fatal brain damage.

READ: Seelos Therapeutics has catalysts for its ketamine depression drug, multiple shots on goal with a strong pipeline

“We are truly excited to be working with the EMA to formulate the Sanfilippo study in the EU,” said Dr. Raj Mehra, the chairman and CEO of Seelos, in a statement. “There are currently no approved therapies in the EU for this devastating neurological condition.”

A meeting with the EMA is critical as it offers guidance and incentives for the research and advance of treatments for rare diseases across the European Union.

Alongside its push into Europe, Seelos has also provided the Food and Drug Administration with a protocol for its planned expanded access study to treat patients with Type C and Type D versions of Sanfilippo as well as patients with Type A and Type B versions of the disease who don’t meet the criteria to enter a Phase 2b/III clinical trial.

Trehalose is promising as it has been shown to reduce the aggregation of misfolded proteins and also help to reduce the accumulation of pathologic material. The way this molecule works is that it triggers autophagy (the body’s means of purging itself of damaged cells) via the activation of transcription factor EB (TFEB), a critical factor in lysosomal and autophagy gene expression.

Diseases which are connected by the common factor of protein aggregations include Sanfilippo syndrome, Oculopharyngeal Muscular Dystrophy (OPMD), Spinocrebellar Ataxia (SCA3), Parkinson’s Disease, Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease, Huntington’s disease and Friedrich Ataxia (FA).

Quick facts: Seelos Therapeutics

Price: 0.9304 USD

NASDAQ:SEEL
Market: NASDAQ
Market Cap: $25.15 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Seelos Therapeutics named herein, including the promotion by the Company of Seelos Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Seelos Therapeutics rings the Nasdaq opening bell

Seelos Therapeutics Inc (NASDAQ: SEEL) CEO Dr Raj Mehra caught up with Proactive after the clinical-stage biopharmaceutical rung the Nasdaq Stock Market opening bell in Times Square, New York. Dr. Mehra says since listing on the exchange in January, the small company has achieved an...

on 08/12/2019

2 min read